North American Neuroendocrine Tumor Society presents:

2010 Neuroendocrine Tumor Symposium Abstracts

NOTICE - Your Javascript is disabled!
Javascript needs to be enabled in order to search the abstracts and receive content updates. Click to read instructions on enabling your Javascript »

Index of Abstracts:

B1

Paraneoplastic antigen Ma2 autoantibodies as a blood biomarker for diagnosis, prognosis and detection of early recurrence of small intestine neuroendocrine tumors

Tao Cui, Monica Hurtig , Graciela Elgue, Su-Chen Li, Giuseppe Pelosi, Ahmed Essaghir, Jean-Baptiste Demoulin, Giulia Veronesi, Mohammad Alimohammadi, Kjell Öberg, Valeria Giandomenico

B2	Changes on Chromosome 18 are Involved in Both Sporadic and Familial Ileal Carcinoid Tumor Development Janet Cunningham, Teresita Diaz de Ståhl Tobias Sjöblom, Gunnar Westin, Jan Dumanski, and Eva Tiensuu Janson Uppsala University, Uppsala. Sweden

B3	Clinical Utility of Genomic Profiling of Pancreatic Neuroendocrine Tumors Michael J Demeure, MD, MBA, Lisa Evers BSc, Elizabeth Lenkiewicz MSc, Tara Holley BSc, Lukas Bubendorf MD, Christian Ruiz PhD, Kimberly J Bussey, PhD, Michael T. Barrett, PhD

B4	An Organ Slice Model to Evaluate Carcinoid Tumorogenesis in Liver Priyodarshan Goswamee, Sasi Arunachalam, Riaz Nasim, Marthe Howard and David R. Giovannucci

B5	Differential Protein Expression in Small Intestinal Carcinoids and Liver Metastases Michelle Kang Kim, Daguan Wang, Miao Cui, Thomas Curran, Stephen Ward, Richard Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz

B6	Are Primary And Metastatic Tumors The Same? Erika Briann Lindholm, MD; Cathy Anthony, PhD; J. Phillip Boudreaux, MD; Abby Gandolfi, MS; Pam Ryan, RN; Yi-Zarn Wang, DDS MD; Eugene A. Woltering, MD

B7	Xanthohumol, a novel plant extract, alters neuroendocrine phenotype and inhibits growth of carcinoid cell lines Catherine M. McManus, BS; Mary Ndiaye BS; Herbert Chen, MD, FACS; Muthusamy Kunnimalaiyaan, PhD

B8	Methods in the Development of Human Carcinoid Cell Lines Eric Sceusi, Asif Rashid, Yunfei Zhou, Shaija Samuel, Fan Fan, Ling Xia, Xiang-Cang Ye, Jia Lu, Federico Tozzi, Puja Gaur, Patrick Zweidler-McKay, Raymond Meyn, James Yao, and Lee M. Ellis

B9

Genetic Associations with Sporadic Neuroendocrine Tumor Risk

Monica Ter-Minassian, Zhaoxi Wang, Kofi Asomaning, Michael C. Wu, Chen-Yu Liu, Jessica K. Paulus, Geoffrey Liu, Penelope A. Bradbury, Rihong Zhai, Li Su, Christine S. Frauenhoffer, Susanne M. Hooshmand, Immaculata DeVivo, Xihong Lin, David C. Christiani, Matthew H. Kulke

B10

Correlation between gene expression profile and tumor behavior of pancreatic neuroendocrine tumors and carcinoids

Yunguang Tong, PhD; Nicholas N. Nissen, MD; Vijay Menon, MD; Edward Wolin, MD; Run Yu, MD, PhD Division of Endocrinology, Department of Surgery, Division of Oncology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, Los Angeles, CA

B11	Hesperitin, a Potential Therapy for Carcinoid Cancer Barbara Zarebczan MD, Scott N. Pinchot MD, Muthusamy Kunnimalaiyaan PhD, Herbert Chen MD

B12	Calcium entry and Maintenance of Oscillatory Ca2+ Signals in Human Carcinoid Cell Lines. Tetyana Zhelay, Sasi Arunachalam and David R. Giovannucci

C1	Presence of Extra-Hepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Carcinoid Arrese David, Feria-Arias Enrique, Hatzaras Ioannis, Guy Gregory, Khabiri Hooman, Schmidt Carl, Shah Manisha, Bloomston Mark

C2	Short Term Response to Systemic I-131 MIBG Therapy in Metastatic Carcinoid Tumors. Richard J Campeau MD, Lowell B Anthony MD, Eugene A Woltering MD, Yi-Zarn Wang MD, and J Phillip Boudreaux MD

C3	Prognostic Criteria Development for Metastatic Well- or moderately-differentiated Neuroendocrine Tumors Lisa M. Caronia, David Arrese, Lai Wei, Carl R. Schmidt, Daria Arbogast, Mark P. Bloomston, Manisha H. Shah

C4

Phase I Study of Pasireotide (SOM230) in Combination with Everolimus (RAD001) in Patients with Advanced Neuroendocrine Tumors (NET)

Jennifer A. Chan, MD, MPH,; David P. Ryan, MD; Charles S. Fuchs, MD, MPH,; Andrew X. Zhu, MD, PhD; Thomas A. Abrams, MD, Brian M. Wolpin, MD, MPH,; Carolyn Casey, BS; Eileen Regan, RN, BSN, OCN; Kristen Cavanaugh, RN; Matthew H. Kulke, MD, MMSc

C5	Phase I Study of Sorafenib in Combination with Everolimus (RAD001) in Patients with Advanced Neuroendocrine Tumors (NET) Jennifer A. Chan, MD, MPH,; Robert J. Mayer, MD,; Nadine Jackson, MD, MPH,; Paige Malinowski, BA; Eileen Regan, RN, BSN, OCN; Matthew H. Kulke, MD, MMSc

C6	Incidental Diagnosis of Pancreatic Neuroendocrine tumors Asima Cheema MD, Jill Weber MPH, Larry Kvols MD, Jonathan Strosberg, MD

C7	Ki-67 Proliferative Index and the Tumor Grade Predict Progression Free Survival in Ileal Carcinoids Deepti Dhall ,Rugvedita Parakh, Richard Mertens, Girish Dhall, Catherine Bresee, Delma Ines, Fai Chung, Marissa Li, Steven D Colquhoun, Nicholas N Nissen, Run Yu, HanlinWang and Edward Wolin

C8

Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo

Pascal Hammel, Daniel Castellano, Eric Van Cutsem, Patricia Niccoli, Sandrine Faivre, Shem Patyna, Deno Klademenos, Dongrui Ray Lu, Richard Chao, Eric Raymond

C9

Phase I/II Study of Everolimus (RAD001) in Combination with Temozolomide (TMZ) in Patients with Advanced Pancreatic Neuroendocrine Tumors (NET)

Matthew H. Kulke, MD, MMSc,; Lawrence Blaszkowsky, MD; Andrew X. Zhu, MD, PhD; Sarah Florio, BS; Eileen Regan, RN, BSN, OCN; David P. Ryan, MD; Jennifer A. Chan, MD, MPH

C10

The Efficacy and Safety of Pasireotide (SOM230) in the Treatment of Patients with Metastatic Neuroendocrine Tumors (NET) Refractory or Resistant to Octreotide LAR

Larry Kvols, Bertram Wiedenmann, Kjell Öberg, Pharis Mohideen, Thomas M. O’Dorisio, Wouter W. de Herder, Gareth Hughes, Rudolf Arnold, Lowell Anthony

C11	An Aggressive Multi-disciplinary Approach to Advanced Neuroendocrine Tumors Shawn MacKenzie, Kambiz Kosari, Timothy Sielaff

C12	Surgical Exploration is Superior to All Other Modalities for Locating Primary Carcinoid Tumors Massimino Kristen P., Han Esther, Pommier SuEllen J., Pommier Rodney F

C13	Small Cell Carcinoma of the Uterine Cervix: A Single-Center Experience Boris G. Naraev, MD, PhD, Michael J. Goodheart, MD, Thomas M. O’Dorisio, MD, Thorvardur R. Halfdanarson, MD

C14

Evaluation of Chromogranin A and Neuron-specific Enolase as Predictors of Response to Everolimus Therapy in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET)

Kjell Öberg, Matthew Kulke, Marianne Pavel, Alexandria Phan, Sakina Hoosen, Jessica St. Peter, Azzeddine Cherfi, and James C. Yao

C15	Predictors of Lymph Node Sampling and Nodal Metastases in Patients with Pancreatic Neuroendocrine Tumors Justin Parekh, MD, Sam C. Wang, MD, Emily K. Bergsland, MD, Alan P. Venook, MD, Robert S. Warren, MD, Grace E. Kim, MD, Eric K. Nakaura, MD, PhD, These authors contributed equally to this work

C16	Cisplatin plus Etoposide in the Management of Metastatic Neuroendocrine Tumors of the Colon and Rectum Patta Annie and Fakih Marwan.G

C17	A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R) in patients with metastatic well differentiated neuroendocrine tumors (NETs) D. L. Reidy, E. Hollywood, M. Segal, L. Saltz

C18	The Addition of Octreotide Functional Imaging to CT or MRI Cross-Sectional Imaging for the Detection of Neuroendocrine Tumors (NETs) - Added Value or an Anachronism? Diane L Reidy, Marc J Gollub, and Leonard B Saltz

C19	Mitotic index and somatostatin receptor status are independent predictors of survival after resection of neuroendocrine tumors metastatic to the liver Sasan Roayaie, Paramjeet Singh, Hongfa Zhu, Lihui Qin, Daniel Labow, Michelle Kim, Richard R. P. Warner, Myron Schwartz

C20	Extensive “Multitasking” Surgery for Advanced Enteropancreatic Neuroendocrine Tumors (NETS): A Safe and Effective Approach Michail Shafir MD, Richard PR Warner MD, Sheilah Gonsalves MD, Jerome J Zacks, MD, Lynn Ratner MD, Michelle Kim MD

C21

Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3)

Manisha H. Shah, Kjell Öberg, Tetsuhide Ito, Catherine Lombard-Bohas, Edward M. Wolin, Eric Van Cutsem, Carolin Sachs, Robert Winkler, Jeremie Lincy, Timothy Hobday and James C. Yao

C22	Hypo/achlorhydria is associated with false-positive secretin stimulation testing (SST) for Zollinger-Ellison syndrome (ZES) Shah, Pari; Yang, Yu-Xiao, ; Metz, David

C23	Multidisciplinary Reference Centers: A Beneficial Approach for Neuroendocrine Tumor Disease Management Simron Singh, Yael Fineberg, and Calvin Law

C24	Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors Jonathan Strosberg MD, Asima Cheema MD, Tiffany Campos, Tiffany Valone PA, Larry Kvols MD

C25	Prognostic Relevance of a Novel AJCC Staging Classification for Neuroendocrine Tumors of the Pancreas Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

C26	Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

C27	Stage I Non-Functioning Neuroendocrine Tumors of the Pancreas: Surgery or Surveillance? Jonathan Strosberg MD, Asima Cheema MD, Larry Kvols MD

C28	Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-based Studies Jonathan Strosberg MD, Thorvardur Halfdanarson MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA ; University of Iowa, Iowa City, Iowa, USA

C29	Expectant Management of the Asymptomatic Primary is Safe in Patients Undergoing Chemoembolization for Metastatic Neuroendocrine Carcinoma Tassone, Patrick; Arrese, David; Klemanski, Dori; Shah, Manisha; Schmidt, Carl; and Bloomston, Mark

C30	Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs) Monica Ter-Minassian, Jennifer A. Chan, Christine S. Frauenhoffer, Susanne M. Hooshmand, Kofi Asomaning, Xihong Lin, David C. Christiani, Matthew H. Kulke

C31	Sunitinib for treatment of pancreatic neuroendocrine tumors: Patient-reported outcomes and efficacy across patient subgroups in a Phase III trial Aaron Vinik, Yung-Jue Bang, Jean-Luc Raoul, Juan Valle, Peter Metrakos, Dieter Hörsch, Beata Korytowsky, Rajiv Mundayat, Richard Chao, Eric Raymond

C32	Radio-guided Exploration Facilitates Surgical Cytoreduction of Neuroendocrine Tumors Yi-Zarn Wang DDS, MD, , Abby E Gandolfi, BS., MS. , Lowell B. Anthony MD, Richard Campeau MD, Eugene Woltering MD. , , and J. Philip Boudreaux MD

C33	Staged Second Look Laparaproscopy: A New Approach for Evaluating Ischemic Bowel Following Extensive Mesenteric Lymphadenectomy for Midgut Carcinoid Yi-Zarn Wang DDS, MD, Eugene Woltering MD and J. Philp Boudreaux MD

C34	Clinical Effect of Temozolomide in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-line Chemotherapy Staffan Welin MD, PhD, Halfdan SorbyeMD, PhD, Sigrunn Sebjornsen MD, Stian Knappskog, PhD, Christian Busch MD, Kjell Öberg MD,PhD

C35	RADIANT-2: A Phase III Trial of Everolimus + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) James C. Yao, John D. Hainsworth, Eric Baudin, Marc Peeters, Dieter Hoersch, Lowell Anthony, Judith Klimovsky, Jessica St. Peter, Valentine Jehl, and Marianne Pavel

C36	Randomized run-in study of Bevacizumab and Everolimus in low- to intermediate- grade neuroendocrine tumors (LGNETs) using perfusion CT (pCT) as functional biomarker James C. Yao, Alexandria Phan, Kenneth R. Hess, David Fogelman, Carmen Jacobs, Cecile G. Dagohoy, Colleen C. Leary, Chaan S. Ng

O1

Somatuline® Autogel® 120 mg (lanreotide) Evaluation of Tumor Progression-Free Survival in Patients with Non-Functioning Entero-Pancreatic Endocrine Tumors: An Ongoing, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study (the CLARINET Study)

Joëlle Blumberg, Edda Gomez-Panzani, Séverine Latapie- Martinezand Nilani Liyanage

O2	LX1606 / LX1032: A Serotonin Synthesis Inhibitor in a Randomized, Double-Blind Phase 2 Clinical Trial in the U.S. as a Novel Approach for Managing Gastrointestinal (GI) Symptoms in Carcinoid Syndrome Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

O3	Open-Label Phase 2 Clinical Trial of LX1606 / LX1032 in Europe: A Novel Agent for Reducing Serotonin Production in Carcinoid Syndrome Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

O4	Bayesian Adaptive Study Design for Efficient Dose Finding for an Octreotide Implant in Patients with Carcinoid Syndrome (CS) Carla Chieffo, Stephen A. Bai, Yusong Chen, Theodore M. Danoff

O5	177 Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms; First Trial in U.S.A Ebrahim S. Delpassand, M.D

O6	An Ongoing, Double-Blind, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline® Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Edda Gomez-Panzani, Stephen Chang, Joëlle Blumberg and Veronique Fohanno

O7	Tumor and Normal Tissue Uptake of 68Ga-DOTA-tyr3- Octreotide after Treatment with Unlabeled Octreotide in Patients with Carcinoid Tumors and Pancreatic Neuroendocrine Tumors Yusuf Menda, MD, Michael Schultz, PhD, David Bushnell, MD, Thomas O’Dorisio, MD, M. Sue O’Dorisio, MD, PhD